These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 19088037)
1. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Pallini R; Ricci-Vitiani L; Banna GL; Signore M; Lombardi D; Todaro M; Stassi G; Martini M; Maira G; Larocca LM; De Maria R Clin Cancer Res; 2008 Dec; 14(24):8205-12. PubMed ID: 19088037 [TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution. Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688 [TBL] [Abstract][Full Text] [Related]
3. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Salnikov AV; Gladkich J; Moldenhauer G; Volm M; Mattern J; Herr I Int J Cancer; 2010 Feb; 126(4):950-8. PubMed ID: 19676044 [TBL] [Abstract][Full Text] [Related]
4. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311 [TBL] [Abstract][Full Text] [Related]
5. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells. Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866 [TBL] [Abstract][Full Text] [Related]
7. Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas. Shin JH; Lee YS; Hong YK; Kang CS J Neurooncol; 2013 Dec; 115(3):333-41. PubMed ID: 24129546 [TBL] [Abstract][Full Text] [Related]
8. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme. Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043 [TBL] [Abstract][Full Text] [Related]
9. Heterogeneous phenotype of human glioblastoma: in vitro study. Denysenko T; Gennero L; Juenemann C; Morra I; Masperi P; Ceroni V; Pragliola A; Ponzetto A; Melcarne A Cell Biochem Funct; 2014 Mar; 32(2):164-76. PubMed ID: 23836332 [TBL] [Abstract][Full Text] [Related]
10. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cell-related gene expression profile in in vitro propagated glioblastoma multiforme-derived cell line with a PNET-like component. Kahlert UD; Bender NO; Maciaczyk D; Bogiel T; Bar EE; Eberhart CG; Nikkhah G; Maciaczyk J Folia Neuropathol; 2012; 50(4):357-68. PubMed ID: 23319191 [TBL] [Abstract][Full Text] [Related]
11. Glioblastoma cancer stem cells--from concept to clinical application. Stopschinski BE; Beier CP; Beier D Cancer Lett; 2013 Sep; 338(1):32-40. PubMed ID: 22668828 [TBL] [Abstract][Full Text] [Related]
12. Correlation between glioblastoma stem-like cells and tumor vascularization. He H; Niu CS; Li MW Oncol Rep; 2012 Jan; 27(1):45-50. PubMed ID: 21971709 [TBL] [Abstract][Full Text] [Related]
13. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Pistollato F; Abbadi S; Rampazzo E; Persano L; Della Puppa A; Frasson C; Sarto E; Scienza R; D'avella D; Basso G Stem Cells; 2010 May; 28(5):851-62. PubMed ID: 20309962 [TBL] [Abstract][Full Text] [Related]
15. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling. Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372 [TBL] [Abstract][Full Text] [Related]
16. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Qiang L; Yang Y; Ma YJ; Chen FH; Zhang LB; Liu W; Qi Q; Lu N; Tao L; Wang XT; You QD; Guo QL Cancer Lett; 2009 Jun; 279(1):13-21. PubMed ID: 19232461 [TBL] [Abstract][Full Text] [Related]
17. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. Lottaz C; Beier D; Meyer K; Kumar P; Hermann A; Schwarz J; Junker M; Oefner PJ; Bogdahn U; Wischhusen J; Spang R; Storch A; Beier CP Cancer Res; 2010 Mar; 70(5):2030-40. PubMed ID: 20145155 [TBL] [Abstract][Full Text] [Related]
18. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Kim KJ; Lee KH; Kim HS; Moon KS; Jung TY; Jung S; Lee MC Neuropathology; 2011 Oct; 31(5):494-502. PubMed ID: 21269333 [TBL] [Abstract][Full Text] [Related]
19. Clinical value of CD133 and nestin in patients with glioma: a population-based study. Dahlrot RH; Hansen S; Jensen SS; Schrøder HD; Hjelmborg J; Kristensen BW Int J Clin Exp Pathol; 2014; 7(7):3739-51. PubMed ID: 25120750 [TBL] [Abstract][Full Text] [Related]
20. Brain tumor stem cells from an adenoid glioblastoma multiforme. Oka N; Soeda A; Noda S; Iwama T Neurol Med Chir (Tokyo); 2009 Apr; 49(4):146-50; discussion 150-1. PubMed ID: 19398857 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]